Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAIT-TOX: Gait Analysis in Focal Dystonia Before and After Botulinum Toxin
NCT03938363Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of neuronox in cervical dystonia (CD) and benign essential blepharospasm (BEB) (4 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Gait Velocity at 5 minutes. Started Oct 2019; status: completed.
02
Drugs
neuronox
03
Conditions
cervical dystonia (CD)benign essential blepharospasm (BEB)
Beyond the preview
Go deeper on NCT03938363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938363.